1Gladman DD,Antoni C,Mease P. Psoriatic arthritis:epidemiology,clinical features,course,and outcome[J].Annals of the Rheumatic Diseases,2005,(suppl 2):ii14.
3Al-suwaidan Dan,Feldman SR. Clearance is not a reaslistic expectation of psoriasis treamen[J].JAM Aca Dermatol,2000,(5 Pt 1):796.
4Mc Cormack,Paul L. Calcipottiol/betamethasone dipropionate:a review of its use in the treatment of psoriasis vulgaris of the trunk,limbs and scalp[J].Drogs,2011,(06):709.
6Van R ossum MM,Van Erp PE,Van de Kerkhof PC. Treatment of psoriasis with a new combination of calcipotriol and batam-etasone dipropionate:a flowcytometric study[J].Dermatlogy,2001,(02):148.
7Mease pJ. Psoriatic arthritis:update on pathophysiology,assessment and management[J].Annals of the Rheumatic Diseases,2011,(suppl 1):i77.
8Mease PJ,Antoni CE,Gladman DD. Psoriatic arthritis assessment tools in clinical trials[J].Annals of the Rheumatic Diseases,2005,(suppl 2):ii49.
9Bakker MF,Jacobs JW,Verstappen SM. Tight control in the treatment of rheumatoid arthritis:efficacy and feasibility[J].Annals of the Rheumatic Diseases,2007,(Suppl 3):iii56.
10Clegg DO,Reda DJ,Abdellatif M. Comparison of sulfasalazine and placebo for the treatment of axial and peripheral articular manifestations of the seronegative spondylarthropathies:a departnent of veterans affairs cooperative study[J].Arthritis and Rheumatism,1999,(11):2325.
二级参考文献10
1Kimball AB, Jacobson C, Weiss S, et al. The psychosocial burden of psoriasis. Am J Clin Dermatol, 2005, 6(6): 383-392.
2Rapp SR, Feldman SR, Exum ML, et al. Psoriasis causes as much disability as other major medical diseases. J Am Aead Dermatol, 1999, 41(3 Pt 1): 401-407.
3Norris DA. Mechanisms of action of topical therapies and the rationale for combination therapy.J Am Acad Dermatol, 2005, 53(1 Suppl 1): S17-25.
4Charakida A, Dadzie O, Teixeira F, et al. Calcipotriol/beta- methasone dipropionate for the treatment of psoriasis.Expert Opin Pharmacother, 2006, 7(5): 597-606.
5Simonsen L, Hoy G, Didriksen E, et al. Development of a new formulation combining calcipotriol and betamethasone dipropionate in an ointment vehicle. Drug Dev Indust Pharm, 2004, 30( 10): 1095-1102.
6Saraceno R, Andreassi L, Ayala F, et al. Efficacy, safety and quality of life of calcipotriol/betamethasone dipropionate (Dovobet) versus calcipotriol (Daivonex) in the treatment of psoriasis vulgaris: a randomized, multicentre, clinical trial. J Dermatolog Treat, 2007, 18(6): 361-365.
7Vakirlis E, Kastanis A, loannides D. Calcipotriol/betamethasone dipropionate in the treatment of psoriasis vulgaris. Ther Clin Risk Manag, 2008, 4( 1 ): 141-148.
8Anstey AV, Kragballe K. Retrospective assessment of PASI 50 and PASI 75 attainment with a calcipotriol/betamethasone dipropionate ointment. Int J Dermatol, 2006, 45(8 ): 970-975.
9Kragballe K, Austad J, Barnes L, et al. A 52-week randomized safety study of a calcipotriol/betamethasone dipropionate two-compound product (Dovobet/Daivobet/Taclonex) in the treatment of psoriasis vulgaris. Br J Derrnatol, 2006, 154(6): 1155-1160.
10Kragballe K, van de Kerkhof PC. Consistency of data in six phase III clinical studies of a two-compound product containing calcipotriol and betamethasone dipropionate ointment for the treatment of psoriasis. J Eur Acad Delmatol Venereol, 2006, 20 (1): 39-44.
